Back to today’s briefing

Story perspectives

Wegovy Approved for MASH: Weight-Loss Market Heating Up

8/29/2025

23 5

Summary

Story summary

Novo Nordisk's Wegovy gained FDA approval for treating metabolic dysfunction-associated steatohepatitis (MASH), expanding its market potential.
The MASH treatment market is projected to grow from $2.47 billion in 2024 to $8.38 billion by 2033.
Teva introduced a generic version of Saxenda, increasing competition in the weight-loss market.
Analysts expect Wegovy's approval to improve MASH diagnosis rates and alter treatment approaches.

1 of 1

Story summary

Novo Nordisk's Wegovy gained FDA approval for treating metabolic dysfunction-associated steatohepatitis (MASH), expanding its market potential.
The MASH treatment market is projected to grow from $2.47 billion in 2024 to $8.38 billion by 2033.
Teva introduced a generic version of Saxenda, increasing competition in the weight-loss market.
Analysts expect Wegovy's approval to improve MASH diagnosis rates and alter treatment approaches.